GlassScriptPhysician profile
Maha M Dawood
NPI 1730166851
$14,793.37
in general payments reported to CMS, 2019-2025
49 companies · $2,458 in 2025
The $2,458 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,600 · 2020: $1,393 · 2021: $2,402 · 2022: $2,349 · 2023: $2,230 · 2024: $2,362 · 2025: $2,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,718 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,717.67 |
| Education | $331.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,621.32 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Janssen Biotech, INC. | $1,428.36 | 2019-2025 | Tremfya, Stelara, Simponi |
| Amgen INC. | $1,271.35 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Pfizer INC. | $845.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $819.33 | 2019-2025 | |
| Ucb, INC. | $742.86 | 2019-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $665.75 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $652.53 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $605.32 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $592.18 | 2019-2024 | Taltz, Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.63 | 2019-2023 | Xifaxan, Plenvu, Relistor |
| Horizon Therapeutics Plc | $343.16 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $269.45 | 2019-2025 | Gazyva |
| Genzyme Corporation | $251.27 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $236.71 | 2020-2025 | Acthar |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maha Dawood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.